Nektar Therapeutics  

(Public, NASDAQ:NKTR)   Watch this stock  
Find more results for Schering Corporation´┐Ż
11.87
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 9.51 - 17.53
Open     -
Vol / Avg. 0.00/1.92M
Mkt cap 1.56B
P/E 68.45
Div/yield     -
EPS 0.17
Shares 131.53M
Beta 1.50
Inst. own 97%
Jul 29, 2015
Q2 2015 Nektar Therapeutics Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 16, 2015
Nektar Therapeutics Annual Shareholders Meeting - 2:00PM EDT - Add to calendar
Apr 30, 2015
Q1 2015 Nektar Therapeutics Earnings Call - Webcast
Apr 30, 2015
Q1 2015 Nektar Therapeutics Earnings Release
Apr 15, 2015
Nektar Therapeutics at Needham Healthcare Conference
Mar 17, 2015
Nektar Therapeutics Conference Call to Discuss the results from Phase 3 BEACON study evaluating single-agent NKTR-102 - Webcast
Feb 24, 2015
Q4 2014 Nektar Therapeutics Earnings Call - Webcast
Feb 24, 2015
Q4 2014 Nektar Therapeutics Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 31.08% -26.86%
Operating margin 39.56% -8.21%
EBITD margin - -1.77%
Return on average assets 28.84% -12.31%
Return on average equity 238.75% -
Employees 438 -
CDP Score - -

Address

455 Mission Bay Blvd S
SAN FRANCISCO, CA 94158-2158
United States - Map
+1-415-4825300 (Phone)
+1-415-3395300 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of drug candidates that utilizes its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of molecular entities that targets known mechanisms of action. Its pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives and immunology. The Company’s research and development activities involve small molecule drugs, peptides and other biologic drug candidates. The Company’s products are Naloxegol and Naloxegol Fixed-Dose Combination Products, Etirinotecan pegol, BAY41-6551, NKTR-181, NKTR-171, NKTR-192 and NKTR-214.

Officers and directors

Robert B. Chess Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Howard W. Robin President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
John Nicholson Chief Financial Officer, Senior Vice President
Age: 63
Bio & Compensation  - Reuters
Jillian B. Thomsen Senior Vice President - Finance, Chief Accounting Officer
Age: 49
Bio & Compensation  - Reuters
Stephen K. Doberstein Ph.D. Senior Vice President, Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Gilbert M. Labrucherie J.D. Senior Vice President, General Counsel, Secretary
Age: 42
Bio & Compensation  - Reuters
Ivan P. Gergel M.D. Senior Vice President - Drug Development & Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Maninder Hora Ph.D. Senior Vice President - Pharmaceutical Development and Manufacturing Operations
Age: 61
Bio & Compensation  - Reuters
R. Scott Greer Independent Director
Age: 56
Bio & Compensation  - Reuters
Joseph J. Krivulka Independent Director
Age: 63
Bio & Compensation  - Reuters